未找到相关数据
Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer
被引：82
作者：
Slamon, D. J.
Eiermann, W.
Robert, N. J.
Giermek, J.
Martin, M.
Jasiowka, M.
Mackey, J. R.
Chan, A.
Liu, M-C
Pinter, T.
Valero, V.
Falkson, C.
Fornander, T.
Shiftan, T. A.
Bensfia, S.
Hitler, S.
Xu, N.
Bee-Munteanu, V.
Drevot, P.
Press, M. F.
Crown, J.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] GBG, Munich, Germany
[3] USO, The Woodlands, TX USA
[4] Maria Sklodowska Curie Ctr, Warsaw, Poland
[5] GEICAM, Madrid, Spain
[6] Maria Sklodowska Curie Mem Canc Inst, Krakow, Poland
[7] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[8] Breast Canc Res Ctr WA, Perth, WA, Australia
[9] Curtin Univ, Perth, WA 6845, Australia
[10] Sun Yat Sen Canc Ctr, Taipei, Taiwan
[11] Petz Aladar Megyei Oktato Korhaz Onkoradiol, Gyor, Hungary
[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[13] Univ Alabama Birmingham, Birmingham, AL USA
[14] Karolinska Univ Hosp, Stockholm, Sweden
[15] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA
[16] Sanofi, Cambridge, England
[17] Sanofi, Chilly Mazarin, France
[18] Genentech Inc, San Francisco, CA USA
[19] TRIO, Paris, France
[20] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[21] ICORG, Dublin, Ireland
来源：
关键词：
D O I：
10.1158/1538-7445.SABCS15-S5-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S5-04
引用
收藏
页数：2
相关论文